期刊文献+

肿瘤坏死因子α对人肺腺癌细胞耐顺铂的影响 被引量:1

The effects of tumor necrosis factor-or on the cisplatin-resistant human lung adenocarcinoma cell lines A549/DDP
原文传递
导出
摘要 目的研究肿瘤坏死因子OL(TNF-α)对人肺腺癌细胞系A549/顺铂(DDP)耐DDP的逆转作用,探讨其与肺耐药相关蛋白(LRP)表达之间的关系。方法以MTT法检0n,0TNF-α与顺铂联用对A549/DDP细胞的细胞毒性作用,以免疫细胞化学方法检测A549/DDP细胞LRP的表达情况。结果250、1000U/mlTNF-α可使顺铂对A549/DDP细胞的IC50从7.12ng/L分别降至5.02、4.41ng/L,能够逆转A549/DDP对顺铂的耐药,逆转倍数分别为1.42、1.62。A549/DDP细胞LRP呈强阳性表达,250、1000U/mlTN-α与顺铂联用可以下调LRP表达,LRP阳性表达率分别为(60.14-4-6.54)%、(57.234-5.98)%,同无药组和顺铂组LRP表达率(79.63±4.78)%、(75.97±5.32)%比较,差异具有统计学意义(P均〈0.01)。结论TNF-α能够逆转A549/DDP对顺铂的耐药,其机制可能与下调LRP表达有关。 Objective To investigate the effects of tumor necrosis factor-α (TNF-α) on the resensitization of human lung cancer cell lines A549/DDP to cisplatin (DDP) and to explore the relationship between the expression of TNF-αand resistance-related protein (LRP) in lung tissue. Methods The cytotoxic effects of combinational treatment by TNF-α and cisplatin on A549/DDP were measured by MTF assay. The expression of LRP was assessed by immunocytochemistry methods. Results The IC50 of A549/DDP to cisplatin were decreased from 7. 12 ng/L to 5.02 ng/L,4. 41 ng/L respectively by 250 U/ml and 1000 U/ml TNF-α treatment (P 〈 0. 01 ), with the sensitivity of A549/DDP to cisplatin increased by 1.42 and 1.62 fold respectively. LRP was overexpressed in A549/DDP cell. 250 U/ml or 1000 U/ml TNF-oL plus cisplatin treatment down-regulated the expression of LRP with the positive rates of ( 60. 14 ± 6. 54 ) % and ( 57.23 ± 5.98 ) % respectively, which were significantly lower than that of cisplatin alone treatment (75.97 ±5.32 ) % and control group (79. 63± 4. 78 ) % ( both P 〈 0. 01 ). Conclusion Tumor necrosis factor-or can reverse the resistance of A549/DDP to cisplatin, which may be partially attributed to down-regulating LRP expression.
出处 《中国综合临床》 2012年第4期347-350,共4页 Clinical Medicine of China
基金 :河南省卫生厅医学科技攻关项目[(2007)185号]
关键词 肿瘤坏死因子Α A549 顺铂 肺耐药相关蛋白 Tumor necrosis factor-et A549 Cisplatin Lung resistance-related protein
  • 相关文献

参考文献12

二级参考文献79

共引文献42

同被引文献26

  • 1Korpanty G, Smyth E, Carney DN. Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? [J]. Thorac Dis, 2011,3 ( 1 ) : 19-29.
  • 2Koch A, Bergman B, Holmberg E, et al. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase 1I trial (CYCLUS study) by the Swedish Lung Cancer Study Group[J]. Eur J Cancer, 2011,47(10) : 1546-1555.
  • 3Mutter R,Lu B,Carbone DP,et al. A phase lI study of celecoxib in combination with paclitaxel,carboplatin, and radiotherapy for patients with inoperable stage 11I A/B non-small cell lung cancer [J]. Clin Cancer Res,2009,5(6) :2158-2165.
  • 4Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclooxygenase 2 inhibitor, enhances the response to preopera- tive paclitaxel and carboplatin in early-stage non small cell lung cancer[J]. J Clin Oncol,2003,21(14) :2645-2650.
  • 5Nugent FW, Mertens WC, Graziano S, et al. Docetaxel and cy- clooxygenase-2 inhibition with celecoxib for advanced non-small- cell lung cancer progressing after platinum-based chemotherapy: a multicancer phase II trial[J]. Lung Cancer, 2005,48 (2) : 267- 273.
  • 6Groen H J, Sietsma H, Vincent A, et al. Randomized, placebo-con- trolled phase m study of docetaxel plus carboplatin with celeeox- ib and cyclooxygenase-2 expression as a biomarker for patients with advanced non small cell lung cancer; the NVALT 4 study [J]. J Clin Oncol, 2011,9(32) :4320-4326.
  • 7孙丽梅,王鲁建,范军,赵海花,何安光.肺癌组织中Cox-2蛋白表达及对预后影响的研究[J].中华肿瘤防治杂志,2007,14(23):1789-1791. 被引量:11
  • 8熊建萍,项晓军,张凌,钟陆行,陈文艳,余峰.长春瑞滨加顺铂联合COX-2抑制剂治疗晚期非小细胞肺癌临床分析[J].肿瘤防治研究,2008,35(3):201-203. 被引量:4
  • 9王志杰,段建春,郭庆志,危志刚,薛卫诚,吴梅娜,赵军,杨鹭,安彤同,刘叙仪,王洁.含铂方案联合西乐葆一线治疗晚期非小细胞肺癌的Ⅱ期临床研究[J].中国肺癌杂志,2008,11(3):425-430. 被引量:4
  • 10黄凌云,徐安健,蒋单懿,郝佳,谷俊朝,肖雪媛,何大澄.非小细胞肺癌血清标志蛋白HSP90α的鉴定及其临床意义[J].国际外科学杂志,2010,37(1):24-28. 被引量:16

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部